Skip to main content
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 8/2019

10.05.2019 | Correspondence

Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient

verfasst von: Ian Downie, MD, Zachary Liederman, MD, FRCPC, Kartiga Thiyagarajah, MD, Rita Selby, MBBS, FRCPC, MSc, Yulia Lin, MD, FRCPC, CTBS

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor,
Table
APTT and anti-Xa assay values as well as factor VIII, fibrinogen, and antithrombin levels of the patient described
Postoperative day
Time
APTT*
(23–30 sec)
Anti-Xa assay†
(0.3–0.7 IU·mL−1)
FVIII ‡
(> 0.50 IU·mL−1)
Fibrinogen
(> 1.70 g·L−1)
Antithrombin
(> 0.33 IU·mL−1)
28
13:18
17.1
0.09
6.286
-
-
 
15:57
34.4
0.73
6.517
-
-
 
17:08
50.6
0.94
5.471
-
-
29
17:56
-
-
6.514
2.29
1.14
30
01:53
17.1
-
5.575
-
-
 
20:53
-
-
-
2.11
-
33
07:22
64.0
1.22
6.199
-
-
34
18:18
44.3
0.71
6.572
-
-
The target APTT range during this time period was 70–90.9 sec. APTT = activated partial thromboplastin time; IU = international units
*APTT reagent – Dade Actin® FS on Sysmex CS 5100; †Anti-Xa assay – Innovance ® Heparin on Sysmex CS 5100; ‡One stage Factor VIII assay on Sysmex CS 5100
Literatur
1.
Zurück zum Zitat Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.CrossRef Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.CrossRef
2.
Zurück zum Zitat Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 282-98. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 282-98.
3.
Zurück zum Zitat Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-4.CrossRefPubMed Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-4.CrossRefPubMed
4.
Zurück zum Zitat Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.CrossRefPubMed Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.CrossRefPubMed
5.
Zurück zum Zitat Young E, Prins M, Levine M, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.CrossRefPubMed Young E, Prins M, Levine M, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.CrossRefPubMed
Metadaten
Titel
Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient
verfasst von
Ian Downie, MD
Zachary Liederman, MD, FRCPC
Kartiga Thiyagarajah, MD
Rita Selby, MBBS, FRCPC, MSc
Yulia Lin, MD, FRCPC, CTBS
Publikationsdatum
10.05.2019
Verlag
Springer International Publishing
Erschienen in
Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 8/2019
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI
https://doi.org/10.1007/s12630-019-01391-y

Weitere Artikel der Ausgabe 8/2019

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 8/2019 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.